271 related articles for article (PubMed ID: 19755158)
1. Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: influence of the formulation parameters.
Gelperina S; Maksimenko O; Khalansky A; Vanchugova L; Shipulo E; Abbasova K; Berdiev R; Wohlfart S; Chepurnova N; Kreuter J
Eur J Pharm Biopharm; 2010 Feb; 74(2):157-63. PubMed ID: 19755158
[TBL] [Abstract][Full Text] [Related]
2. Effects of surface modification of PLGA-PEG-PLGA nanoparticles on loperamide delivery efficiency across the blood-brain barrier.
Chen YC; Hsieh WY; Lee WF; Zeng DT
J Biomater Appl; 2013 Mar; 27(7):909-22. PubMed ID: 22207601
[TBL] [Abstract][Full Text] [Related]
3. [The delivery of loperamide to the brain by using polybutyl cyanoacrylate nanoparticles].
Aliautdin RN; Petrov VE; Langer K; Berthold A; Kreuter J; Kharkevich DA
Eksp Klin Farmakol; 1998; 61(1):17-20. PubMed ID: 9575405
[TBL] [Abstract][Full Text] [Related]
4. Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles.
Wilson B; Samanta MK; Santhi K; Kumar KP; Paramakrishnan N; Suresh B
Eur J Pharm Biopharm; 2008 Sep; 70(1):75-84. PubMed ID: 18472255
[TBL] [Abstract][Full Text] [Related]
5. Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain.
Michaelis K; Hoffmann MM; Dreis S; Herbert E; Alyautdin RN; Michaelis M; Kreuter J; Langer K
J Pharmacol Exp Ther; 2006 Jun; 317(3):1246-53. PubMed ID: 16554356
[TBL] [Abstract][Full Text] [Related]
6. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease.
Wilson B; Samanta MK; Santhi K; Kumar KP; Paramakrishnan N; Suresh B
Brain Res; 2008 Mar; 1200():159-68. PubMed ID: 18291351
[TBL] [Abstract][Full Text] [Related]
7. Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB).
Ulbrich K; Hekmatara T; Herbert E; Kreuter J
Eur J Pharm Biopharm; 2009 Feb; 71(2):251-6. PubMed ID: 18805484
[TBL] [Abstract][Full Text] [Related]
8. Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles.
Kurakhmaeva KB; Djindjikhashvili IA; Petrov VE; Balabanyan VU; Voronina TA; Trofimov SS; Kreuter J; Gelperina S; Begley D; Alyautdin RN
J Drug Target; 2009 Sep; 17(8):564-74. PubMed ID: 19694610
[TBL] [Abstract][Full Text] [Related]
9. Kinetics of transport of doxorubicin bound to nanoparticles across the blood-brain barrier.
Wohlfart S; Khalansky AS; Gelperina S; Begley D; Kreuter J
J Control Release; 2011 Aug; 154(1):103-7. PubMed ID: 21616104
[TBL] [Abstract][Full Text] [Related]
10. Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin.
Yadav AK; Mishra P; Mishra AK; Mishra P; Jain S; Agrawal GP
Nanomedicine; 2007 Dec; 3(4):246-57. PubMed ID: 18068091
[TBL] [Abstract][Full Text] [Related]
11. The effect of surface functionalization of PLGA nanoparticles by heparin- or chitosan-conjugated Pluronic on tumor targeting.
Chung YI; Kim JC; Kim YH; Tae G; Lee SY; Kim K; Kwon IC
J Control Release; 2010 May; 143(3):374-82. PubMed ID: 20109508
[TBL] [Abstract][Full Text] [Related]
12. Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123.
Tosi G; Costantino L; Rivasi F; Ruozi B; Leo E; Vergoni AV; Tacchi R; Bertolini A; Vandelli MA; Forni F
J Control Release; 2007 Sep; 122(1):1-9. PubMed ID: 17651855
[TBL] [Abstract][Full Text] [Related]
13. Design and optimization of NSAID loaded nanoparticles.
Sashmal S; Mukherjee S; Ray S; Thakur RS; Ghosh LK; Gupta BK
Pak J Pharm Sci; 2007 Apr; 20(2):157-62. PubMed ID: 17416573
[TBL] [Abstract][Full Text] [Related]
14. Sialic acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: In vivo pharmacological evidence and biodistribution.
Tosi G; Vergoni AV; Ruozi B; Bondioli L; Badiali L; Rivasi F; Costantino L; Forni F; Vandelli MA
J Control Release; 2010 Jul; 145(1):49-57. PubMed ID: 20338201
[TBL] [Abstract][Full Text] [Related]
15. Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain.
Kreuter J; Hekmatara T; Dreis S; Vogel T; Gelperina S; Langer K
J Control Release; 2007 Mar; 118(1):54-8. PubMed ID: 17250920
[TBL] [Abstract][Full Text] [Related]
16. Treatment of glioblastoma with poly(isohexyl cyanoacrylate) nanoparticles.
Wohlfart S; Khalansky AS; Bernreuther C; Michaelis M; Cinatl J; Glatzel M; Kreuter J
Int J Pharm; 2011 Aug; 415(1-2):244-51. PubMed ID: 21641983
[TBL] [Abstract][Full Text] [Related]
17. On the design of in situ forming biodegradable parenteral depot systems based on insulin loaded dialkylaminoalkyl-amine-poly(vinyl alcohol)-g-poly(lactide-co-glycolide) nanoparticles.
Packhaeuser CB; Kissel T
J Control Release; 2007 Nov; 123(2):131-40. PubMed ID: 17854938
[TBL] [Abstract][Full Text] [Related]
18. Influence of the formulation on the tolerance profile of nanoparticle-bound doxorubicin in healthy rats: focus on cardio- and testicular toxicity.
Pereverzeva E; Treschalin I; Bodyagin D; Maksimenko O; Langer K; Dreis S; Asmussen B; Kreuter J; Gelperina S
Int J Pharm; 2007 Jun; 337(1-2):346-56. PubMed ID: 17306479
[TBL] [Abstract][Full Text] [Related]
19. Preparation and therapeutic efficacy of polysorbate-80-coated amphotericin B/PLA-b-PEG nanoparticles.
Ren T; Xu N; Cao C; Yuan W; Yu X; Chen J; Ren J
J Biomater Sci Polym Ed; 2009; 20(10):1369-80. PubMed ID: 19622277
[TBL] [Abstract][Full Text] [Related]
20. Non-aggregated protamine-coated poly(lactide-co-glycolide) nanoparticles of cisplatin crossed blood-brain barrier, enhanced drug delivery and improved therapeutic index in glioblastoma cells: in vitro studies.
Dhami NK; Pandey RS; Jain UK; Chandra R; Madan J
J Microencapsul; 2014; 31(7):685-93. PubMed ID: 24963955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]